Journal
NEUROLOGY
Volume 89, Issue 10, Pages 1028-1034Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000004336
Keywords
-
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- Bio-Clinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- Canadian Institutes of Health Research
- National Health & Medical Research Council-Australian Research Council (NHMRC-ARC) Dementia Research Development Fellowship [APP1111603]
- NIH [K01 AG051718]
Ask authors/readers for more resources
Objective: To clarify associations between APOE epsilon 4 allele and age on longitudinal rates of b-amyloid (Ab) accumulation within A beta+ and A beta-older individuals without dementia. Methods: We analyzed 595 older adults without dementia classified cross-sectionally as A beta- (n 5 325) and A beta+ (n 5 270) using longitudinal florbetapir PET. The influence of age and APOE genotype on longitudinal accumulation of Ab was examined with linear mixed models. Results: APOE epsilon 4 and older age were associated with higher risk of being classified as A beta+ at baseline. The annual rate of Ab accumulation was significantly greater than zero for A beta-epsilon 3 (0.0021 6 0.0007 standardized uptake value ratio [ SUVR] units) and A beta-epsilon 4 (0.0044 6 0.0010 SUVR units), as well as A beta+ epsilon 3 (0.0141 6 0.0019 SUVR units) and A beta+ epsilon 4 (0.0126 6 0.0018 SUVR units). Ab accumulation was significantly faster in A beta-epsilon 4 compared to A beta-epsilon 3 and A beta-epsilon 2. Rates of Ab accumulation did not differ significantly between A beta+ APOE groups. Older age was associated with higher rates of Ab accumulation in the A beta-group. Conclusions: APOE epsilon 4 carriage and older age were predictors of longitudinal Ab accumulation within the A beta-group but not the A beta+ group. APOE epsilon 2 carriage was protective against longitudinal Ab accumulation within the A beta-group. APOE genotype in conjunction with chronologic age may aid in participant selection for primary prevention trials aimed at halting Ab accumulation before abnormal levels are reached.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available